FLEBOGAMMA 10% DIF normal immunoglobulin (Human) 10g/100mL intravenous use injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

flebogamma 10% dif normal immunoglobulin (human) 10g/100ml intravenous use injection vial

grifols australia pty ltd - normal immunoglobulin, quantity: 10 g - injection, solution - excipient ingredients: human immunoglobulin a; water for injections; sorbitol - replacement therapy indications: - primary immunodeficiency (pi) diseases - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,immunomodulation indications: - idiopathic thrombocytopaenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count. - guillain barr? syndrome - kawasaki disease.

HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 10 mL pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

hizentra human normal immunoglobulin 20% solution for subcutaneous injection 10 ml pre-filled syringe

csl behring australia pty ltd - normal immunoglobulin, quantity: 2 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 5 mL pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

hizentra human normal immunoglobulin 20% solution for subcutaneous injection 5 ml pre-filled syringe

csl behring australia pty ltd - normal immunoglobulin, quantity: 1 g - injection, solution - excipient ingredients: water for injections; proline; polysorbate 80 - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 5 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hizentra human normal immunoglobulin 20% solution for subcutaneous injection 5 ml vial

csl behring australia pty ltd - normal immunoglobulin, quantity: 1 g - injection, solution - excipient ingredients: water for injections; proline; polysorbate 80 - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 10 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hizentra human normal immunoglobulin 20% solution for subcutaneous injection 10 ml vial

csl behring australia pty ltd - normal immunoglobulin, quantity: 2 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 50 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hizentra human normal immunoglobulin 20% solution for subcutaneous injection 50 ml vial

csl behring australia pty ltd - normal immunoglobulin, quantity: 10 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 20 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hizentra human normal immunoglobulin 20% solution for subcutaneous injection 20 ml vial

csl behring australia pty ltd - normal immunoglobulin, quantity: 4 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

FLEBOGAMMA 5% DIF Human normal immunoglobulin 20g/400mL intravenous use injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

flebogamma 5% dif human normal immunoglobulin 20g/400ml intravenous use injection vial

grifols australia pty ltd - normal immunoglobulin, quantity: 50 mg/ml - injection, intravenous infusion - excipient ingredients: human immunoglobulin a; water for injections; sorbitol - replacement therapy in: primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiency, wiskott aldrich syndrome; myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; and children with congenital aids and recurrent infections. immunomodulation: idiopathic thrombocytopenia purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count, guillian barre syndrome. allogenic bone marrow transplantation.

FLEBOGAMMA 5% DIF Human normal immunoglobulin 10g/200mL intravenous use injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

flebogamma 5% dif human normal immunoglobulin 10g/200ml intravenous use injection vial

grifols australia pty ltd - normal immunoglobulin, quantity: 50 mg/ml - injection, intravenous infusion - excipient ingredients: human immunoglobulin a; sorbitol; water for injections - replacement therapy in: primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiency, wiskott aldrich syndrome; myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; and children with congenital aids and recurrent infections. immunomodulation: idiopathic thrombocytopenia purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count, guillian barre syndrome. allogenic bone marrow transplantation.

FLEBOGAMMA 5% DIF Human normal immunoglobulin 5g/100mL intravenous use injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

flebogamma 5% dif human normal immunoglobulin 5g/100ml intravenous use injection vial

grifols australia pty ltd - normal immunoglobulin, quantity: 50 mg/ml - injection, intravenous infusion - excipient ingredients: human immunoglobulin a; water for injections; sorbitol - replacement therapy in: primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiency, wiskott aldrich syndrome; myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; and children with congenital aids and recurrent infections. immunomodulation: idiopathic thrombocytopenia purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count, guillian barre syndrome. allogenic bone marrow transplantation.